When you are co-founder of a company developing a technology that could potentially improve the treatment of atrial fibrillation (AF), finding time to talk about important clinical milestones can be tricky — especially when such achievements occur just as one of the largest annual arrhythmia-focused meetings is getting underway. (Medical Device Daily) Read More
